The Classic Egg-Yolk Macular Dystrophy of Childhood
Retinal specialists nicknamed this condition after what they saw through the ophthalmoscope more than a century ago: a round, golden-yellow deposit sitting beneath the macula, unmistakably shaped like an egg yolk — vitelliform, from the Latin word for yolk. That deposit doesn't stay static; it moves through a fairly predictable sequence of stages over years, forming, gradually breaking apart, and eventually settling, and it is this staged progression, more than any single symptom, that guides how the condition is followed over time.
One detail regularly catches Ghanaian families off guard at the first consultation: a child can carry a strikingly visible yolk-shaped lesion on examination and still read comfortably at their age level. The appearance of the lesion and the actual level of vision do not necessarily move together, which is exactly why correctly staging the disease matters more than reacting to how dramatic the retinal photograph looks.
In the earliest, classic stage, central vision is often only mildly affected — sometimes not affected at all — even though the lesion itself is clearly visible during examination. Symptoms tend to become noticeable once the once-uniform deposit begins to break apart, a stage often described as resembling a scrambled egg; this is typically when blurred or distorted central vision, along with difficulty with fine print, first appears. In later, more advanced stages, central vision loss becomes more firmly established, and in a smaller number of cases, abnormal blood vessel growth beneath the retina can trigger a further, sudden drop in vision.
Best disease traces back to mutations in the BEST1 gene, which ordinarily produces a protein called bestrophin-1 involved in regulating ion and fluid movement across the retinal pigment epithelium. When that regulation fails, fluid and pigment build up abnormally beneath the macula, forming the characteristic vitelliform lesion. It follows an autosomal dominant pattern, though expressivity varies considerably — some gene carriers show a clearly visible lesion with barely any symptoms, while others in the very same family experience more meaningful changes to their vision.
The electro-oculogram carries most of the diagnostic weight here, flagging a strikingly abnormal Arden ratio even when the eye's ERG reading comes back looking unremarkable — that particular mismatch is what points examiners toward Best disease over other lesions that can look similar at a glance. We use OCT imaging visit after visit to follow the lesion through its various stages, and a positive BEST1 genetic result closes out the diagnosis while also flagging which relatives might be silent carriers worth screening.
Given how often this condition simply sits still for years without changing, our early approach favours patient, staged observation over jumping straight to intervention, with one eye kept firmly on the modest chance of new vessel growth as the lesion continues its slow evolution. Once a patient's vision has genuinely started to decline, we bring regenerative stem cell therapy into the discussion as part of a plan built around holding onto whatever central function is still there.
It is, and it's actually one of the more reassuring, well-documented patterns of early-stage Best disease. Lesion size on a photograph and actual visual function simply don't move in lockstep, which is exactly why we lean on proper staging rather than the drama of the image itself.
No — this stays a self-contained, benign retinal condition with no link to cancer whatsoever. What it does do is progress through a series of recognised stages, and tracking that progression is the whole point of our regular monitoring.
That's variable expressivity at work, a well-known trait of BEST1 mutations. It's quite possible he carries the very same faulty gene without it producing a visible lesion or any symptoms — the only way to know for sure is to have him tested directly rather than assume he's been spared.
No — plenty of patients hold onto good central vision for many years, particularly those whose lesion doesn't progress past its earlier stages. Since the pattern genuinely differs from person to person, staying on top of monitoring is what lets us act quickly if and when things do start to shift.